Category: Press Releases

Tafamidis under review
Tafamidis accepted for FDA Review in 2019
Earlier this month, Pfizer announced that it has made two separate FDA submissions for their drug tafamidis, based on evidence generated from the Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) clinical trial, (more…)
Read More
NICE appraisal for amyloidosis
NICE issue initial negative decisions on inotersen and patisiran
The UK’s National Institute for Health and Care Excellence (NICE) has published Evaluation Consultation Documents on its assessments of inotersen and patisiran. (more…)
Read More
Seminal ARC Manuscript Published
Amyloidosis Research Consortium Announces Publication of Seminal Manuscript in Peer-Reviewed Journal Leukemia Encouraging Use of NT-proBNP as Endpoint in Clinical Trials. International AL amyloidosis expert community agrees N-terminal pro-brain natriuretic peptide (NT-proBNP) is analytically validated and clinically qualified to be...
Read More
Breakthrough on Biomarkers
Amyloidosis Research Consortium Calls For Regulators To Adopt New Surrogate End Point For Pivotal Clinical Trials In Patients with AL Amyloidosis Cardiac functional biomarker is a validated end point used universally by amyloidosis specialists to determine treatment outcomes and to...
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization